A Phase I Pharmacodynamic Study of Copanlisib (BAY 80-6946) as Monotherapy in Patients With Non-Hodgkin's Lymphoma and Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 22 Jun 2017
At a glance
- Drugs Copanlisib (Primary)
- Indications Non-Hodgkin's lymphoma; Solid tumours
- Focus Pharmacodynamics
- Sponsors Bayer
- 10 Jun 2017 Biomarkers information updated
- 06 Apr 2017 Status changed from active, no longer recruiting to completed.
- 14 Feb 2017 Planned End Date changed from 1 Jan 2017 to 1 Feb 2017.